X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (98) 98
selumetinib (93) 93
humans (83) 83
oncology (72) 72
female (44) 44
cancer (41) 41
azd6244 arry-142886 (35) 35
male (35) 35
melanoma (33) 33
open-label (33) 33
animals (31) 31
middle aged (30) 30
pharmacology & pharmacy (30) 30
aged (27) 27
benzimidazoles - administration & dosage (27) 27
arry-142886 (26) 26
adult (25) 25
benzimidazoles - pharmacology (24) 24
mutation (24) 24
protein kinase inhibitors - pharmacology (24) 24
cell line, tumor (23) 23
mek (22) 22
phase-ii (21) 21
research (21) 21
selumetinib azd6244 (20) 20
cell proliferation - drug effects (19) 19
mek inhibitor (19) 19
apoptosis (18) 18
medicine & public health (18) 18
multicenter (18) 18
protein kinase inhibitors - therapeutic use (18) 18
activation (17) 17
azd6244 (17) 17
care and treatment (17) 17
chemotherapy (17) 17
combination (17) 17
kinases (17) 17
kras (17) 17
lung cancer (17) 17
map kinase kinase 1 - antagonists & inhibitors (17) 17
mitogen-activated protein kinase kinases - antagonists & inhibitors (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (16) 16
apoptosis - drug effects (16) 16
benzimidazoles - therapeutic use (16) 16
cell lung-cancer (16) 16
drug therapy (16) 16
mice (16) 16
protein kinase inhibitors - administration & dosage (16) 16
xenograft model antitumor assays (16) 16
map kinase kinase 2 - antagonists & inhibitors (15) 15
metastatic melanoma (15) 15
mutations (15) 15
pathway (15) 15
pharmacology (15) 15
pharmacology/toxicology (15) 15
signal transduction - drug effects (15) 15
survival (15) 15
tumors (15) 15
braf (14) 14
cell biology (14) 14
clinical trials (14) 14
inhibitor azd6244 arry-142886 (14) 14
lung neoplasms - drug therapy (14) 14
mek inhibitors (14) 14
metastasis (14) 14
pharmacokinetics (14) 14
studies (14) 14
antimitotic agents (13) 13
antineoplastic agents (13) 13
antineoplastic agents - pharmacology (13) 13
antineoplastic agents - therapeutic use (13) 13
kinase kinase-1/2 inhibitor (13) 13
neoplasms - drug therapy (13) 13
trametinib (13) 13
article (12) 12
benzimidazoles - adverse effects (12) 12
carcinoma, non-small-cell lung - drug therapy (12) 12
colorectal cancer (12) 12
colorectal neoplasms - drug therapy (12) 12
docetaxel (12) 12
treatment outcome (12) 12
acquired-resistance (11) 11
cancer therapies (11) 11
map kinase signaling system - drug effects (11) 11
melanoma - drug therapy (11) 11
mice, nude (11) 11
phosphorylation (11) 11
protein kinase inhibitors - adverse effects (11) 11
trial (11) 11
administration, oral (10) 10
analysis (10) 10
cells (10) 10
dosage and administration (10) 10
map kinase kinase kinases - antagonists & inhibitors (10) 10
maximum tolerated dose (10) 10
mek1/2 inhibitor (10) 10
neoplasms (10) 10
proto-oncogene proteins p21 - genetics (10) 10
raf (10) 10
signal-regulated kinase (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 12/2016, Volume 27, Issue 12, pp. 2210 - 2215
Journal Article
British Journal of Cancer, ISSN 0007-0920, 02/2012, Volume 106, Issue 5, pp. 858 - 866
BACKGROUND: The Ras/RAF/MEK/ERK pathway is frequently deregulated in cancer and a number of inhibitors that target this pathway are currently in clinical... 
temozolomide | scheduling | apoptosis | Selumetinib | barasertib | docetaxel | PROTEIN | PHOSPHORYLATION | MAP KINASE | G/M TRANSITION | MULTIPLE-MYELOMA CELLS | SPINDLE-CHECKPOINT | IN-VITRO | ONCOLOGY | MELANOMA-CELLS | KINASE KINASE INHIBITION | PHASE-I | Taxoids - pharmacology | Apoptosis - drug effects | Dacarbazine - therapeutic use | Humans | Organophosphates - therapeutic use | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Neoplasms, Experimental - pathology | Taxoids - therapeutic use | Benzimidazoles - administration & dosage | Dacarbazine - pharmacology | Dacarbazine - analogs & derivatives | Female | Quinazolines - administration & dosage | Antineoplastic Agents - pharmacology | Benzimidazoles - therapeutic use | Organophosphates - administration & dosage | MAP Kinase Kinase 1 - antagonists & inhibitors | Dacarbazine - administration & dosage | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Organophosphates - pharmacology | Xenograft Model Antitumor Assays | Taxoids - administration & dosage | Animals | MAP Kinase Signaling System - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | MAP Kinase Kinase 2 - antagonists & inhibitors | Mice, Nude | Quinazolines - therapeutic use | Cell Line, Tumor | Benzimidazoles - pharmacology | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Quinazolines - pharmacology | Neoplasms, Experimental - drug therapy | Translational Therapeutics
Journal Article
Cancer, ISSN 0008-543X, 02/2013, Volume 119, Issue 4, pp. 799 - 805
Journal Article
Scientific Reports, ISSN 2045-2322, 11/2015, Volume 5, Issue 1, pp. 16382 - 16382
AZD6244 (ARRY-142886), a highly selective MAPK-ERK kinase inhibitor, has shown excellent clinical efficacy in many tumors. However, the anti-tumor and... 
TRIAL | MONOTHERAPY | K-RAS | SELUMETINIB AZD6244 | BRAF MUTATIONS | MULTIDISCIPLINARY SCIENCES | PHASE-II | TUMOR ANGIOGENESIS | COMBINATION | EXPRESSION | CHEMOTHERAPY | Humans | Middle Aged | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Male | Stomach Neoplasms - pathology | Vascular Endothelial Growth Factor A - metabolism | Extracellular Signal-Regulated MAP Kinases - metabolism | Molecular Targeted Therapy | Vascular Endothelial Growth Factor A - genetics | Human Umbilical Vein Endothelial Cells - physiology | Hypoxia-Inducible Factor 1, alpha Subunit - metabolism | Angiogenesis Inhibitors - therapeutic use | Female | Gene Expression Regulation, Neoplastic - drug effects | Benzimidazoles - therapeutic use | Stomach Neoplasms - enzymology | Human Umbilical Vein Endothelial Cells - drug effects | Adenocarcinoma - enzymology | Kaplan-Meier Estimate | Angiogenesis Inhibitors - pharmacology | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Xenograft Model Antitumor Assays | Animals | MAP Kinase Signaling System - drug effects | Mice, Nude | Neovascularization, Pathologic - drug therapy | Cell Line, Tumor | Protein Binding | Benzimidazoles - pharmacology | Aged | Mice, Inbred BALB C | Stomach Neoplasms - mortality | Adenocarcinoma - mortality | Phosphorylation | Leukocyte migration | Toxicity | Extracellular signal-regulated kinase | MAP kinase | Kinases | Stomach cancer | Survival | K-Ras protein | Angiogenesis | Xenografts | c-Fos protein | Vascular endothelial growth factor | Gastric cancer | Cell migration | Tumors | Index Medicus
Journal Article
Investigational New Drugs, ISSN 0167-6997, 6/2015, Volume 33, Issue 3, pp. 720 - 728
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 6/2012, Volume 30, Issue 3, pp. 1216 - 1223
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2015, Volume 75, Issue 1, pp. 17 - 23
More than half of colorectal tumors harbor activating mutations in RAS/RAF proteins. Selumetinib (AZD6244, ARRY-142886) is a small molecule kinase inhibitor... 
KRAS mutation | Irinotecan | Colon cancer | Selumetinib | Medicine & Public Health | Oncology | Cancer Research | Pharmacology/Toxicology | MULTICENTER | RESECTION | RATIONAL COMBINATION | IMPROVED SURVIVAL | BRAF | TRIAL | CETUXIMAB | MEK INHIBITOR | ONCOLOGY | PHARMACOLOGY & PHARMACY | KRAS | MUTATIONS | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | ras Proteins - metabolism | Drug Resistance, Neoplasm | Male | Neoplasm Proteins - antagonists & inhibitors | Protein Kinase Inhibitors - adverse effects | Neoplasm Proteins - metabolism | Dose-Response Relationship, Drug | Early Termination of Clinical Trials | Benzimidazoles - administration & dosage | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Benzimidazoles - adverse effects | MAP Kinase Kinase Kinases - antagonists & inhibitors | Colorectal Neoplasms - metabolism | Benzimidazoles - therapeutic use | Camptothecin - analogs & derivatives | Proto-Oncogene Proteins - metabolism | Camptothecin - adverse effects | Camptothecin - therapeutic use | Topoisomerase I Inhibitors - administration & dosage | Proto-Oncogene Proteins - genetics | MAP Kinase Kinase Kinases - metabolism | Protein Kinase Inhibitors - administration & dosage | Pilot Projects | Topoisomerase I Inhibitors - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Topoisomerase I Inhibitors - therapeutic use | Survival Analysis | Aged | Mutation | Cohort Studies | Antimitotic agents | Proteins | Complications and side effects | Care and treatment | Chemotherapy | Anemia | Gastrointestinal diseases | Colorectal cancer | Antineoplastic agents | Cancer
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2013, Volume 31, Issue 1, pp. 30 - 38
Journal Article